BiotechTube

Tovorafenib

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low-grade Glioma

Conditions

Low-grade Glioma

Trial Timeline

— → —

NCT ID
NCT05760586

About Tovorafenib

Tovorafenib is a pre-clinical stage product being developed by Day One Biopharmaceuticals for Low-grade Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT05760586. Target conditions include Low-grade Glioma.

What happened to similar drugs?

0 of 3 similar drugs in Low-grade Glioma were approved

Approved (0) Terminated (1) Active (2)
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05760586Pre-clinicalCompleted
NCT05465174Phase 2Recruiting
NCT04985604Phase 2Terminated
NCT04775485Phase 2Recruiting

Competing Products

13 competing products in Low-grade Glioma

See all competitors
ProductCompanyStageHype Score
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EverolimusNovartisPhase 2
35
MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
32
Fludarabine Phosphate (Fludara) + RituximabSanofiPhase 2
35
rituximabBiogenPhase 3
37
TovorafenibIpsenPhase 1
33
TovorafenibDay One BiopharmaceuticalsPhase 2
36
Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
41
DAY101Day One BiopharmaceuticalsPhase 1
23
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBDTyra BiosciencesPhase 2
36
rhuFlt3L/CDX-301 + Poly-ICLCCelldex TherapeuticsPhase 1/2
26
combined therapy with rh-ES and CVBrain BiotechPhase 2
25